Management attributes Scent's rebound to a rebuilt R&D engine and stronger go-to-market execution, with 2H expected to show mid-single-digit growth for Fine Fragrance and low-single-digit gains for Consumer Fragrance, while Fragrance Ingredients normalizes. The plan emphasizes sustained R&D investment around 8-9% of sales to support a pipeline of molecules, delivery systems, and innovative products through 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management links the recovery to a sustained rebuild of Scent’s innovation engine. They state that ~2.5 years ago the R&D pipeline “was not what it should have been” and that IFF now has a “very strong R&D capability,” with leading-edge new Fine Fragrances and Consumer Fragrances plus a “great pipeline of molecules as well as delivery systems.” 1 This is positioned as closing capability gaps while strengthening strengths, and management explicitly says they are “optimistic about the future of Scent,” even while noting more work remains. 1
Beyond R&D itself, management frames recovery as linked to execution—investing in R&D, growing market share back, and rebuilding the customer go-to-market approach on the Consumer Fragrance side. 2 In addition, they say the Scent team delivered Q2 sales up 8% with strong win performance and increased sales within existing business (volume-driven execution). 34
Management attributes Fine Fragrance performance in part to volatility management. They say the team “did a very good job at managing the challenges in the Middle East,” resulting in Fine Fragrance finishing “up slightly positive” versus an expectation for “mid-single digits” decline into the quarter. 4 They also emphasize that the recovery trajectory into late year is supported by large comparables: Q3 last year grew ~20% YoY, creating a tough comp, but they still expect improvement as they move toward Q4. 4
For Consumer Fragrance, management expects continued improvement but also notes that Q2 was stronger (high single digits) and will normalize. 2 They credit R&D and customer-facing execution: compounds execution and rebuilding R&D capability + go-to-market approach to drive market share gains. 2
While your question is about Fine/Consumer Fragrance evolution, the excerpts show Scent recovery momentum has also been helped by Fragrance Ingredients. They report Q2 Fragrance Ingredients grew “north of 20%” and that it was partially a year-over-year delta (comparing to a down 10% or more prior year period), but also partially underlying improvement via synthetics portfolio leverage amid macro and supply chain pressures. 4 They further say as things settle down, they expect normalization with the forecast reflecting a shift back toward higher value-added ingredients versus traditional synthetics, which will matter for growth rates going forward. 4 They also explicitly expect Fragrance Ingredients to normalize on a go-forward basis and be slightly under pressure YoY. 2
Management provides a directional growth pattern for the second half:
They explicitly connect this to Middle East-related noise and comps:
Management’s expectation is also time-shaped:
So, in summary: Fine Fragrance is expected to rebound more into Q4 (mid-single-digit 2H), while Consumer Fragrance is expected to cool from a strong Q2 to a low-single-digit “go-forward” rate (2H). 2
The excerpts don’t provide a month-by-month “2027 roadmap,” but they do give clear elements of the R&D plan and the strategic logic behind it.
Management states that IFF has moved from a weak pipeline to a strong one:
This is the core “platform” intended to support the business into 2027. 1
On innovation/ROI logic, management emphasizes that they must keep investing in R&D:
Even though this is corporate framing (not only Scent), it directly underpins the idea that R&D is intended to be sustained—i.e., not a one-time fix—supporting 2027 competitiveness. 6
Management adds that some ingredient repositioning takes longer and that this matters beyond 2H:
While that statement is about Fragrance Ingredients specifically, it reinforces that management’s plan is staged—immediate recovery/normalization in 2H, with longer-cycle improvements (including R&D- and portfolio-related) building toward future competitiveness (implicitly including 2027). 2
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent recovery is anchored in a rebuilt R&D engine and stronger go-to-market execution, with near-term tailwinds from fragrance ingredients. 2H 2026 guidance shows Fine Fragrance accelerating into Q4 while Consumer Fragrance normalizes to low single-digit growth, as Middle East volatility subsides. The 2027 plan focuses on a robust pipeline and higher-value ingredient mix to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to a rebuilt R&D engine, stronger perfumers, and improved go-to-market execution, while guiding a softer Q3 and stronger Q4 for Fine Fragrance and a normalized low single-digit path for Consumer Fragrance in 2H. The company also emphasizes an expanded R&D program—molecules, delivery systems, and higher-value ingredients—to sustain growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a strengthened R&D pipeline and a revamped go-to-market strategy, with Consumer Fragrance poised for market-share gains while Fine Fragrance navigates regional volatility. The company frames 2027 as a natural extension of its enhanced R&D capabilities, with a shift toward higher-value, natural ingredients and sustained innovation to support growth in the second half and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi‑driver path to Scent recovery, led by Fragrance Ingredients momentum, improved Consumer and Fine Fragrance execution, and an R&D overhaul aimed at 2027. In 2H, Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes from a high single-digit Q2 growth to a low single-digit trajectory, supported by a revamped product pipeline and go‑to‑market strategy.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, stabilization in Fine Fragrance, and a rebuilt Consumer Fragrance engine anchored by R&D and go-to-market improvements. The 2H 2026 path points to a Q3 softness followed by a Q4 rebound, with a longer runway toward 2027 supported by an 8–9% R&D intensity and a strengthened innovation pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by strong Fragrance Ingredients growth and a rebuilt R&D engine, with a mid-to-long-term plan to enhance market position into 2027. In H2, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance trends toward low single-digit growth as R&D and go-to-market initiatives support share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to robust Fragrance Ingredients growth and an improved R&D pipeline, with plans to support 2027. Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes to a low single-digit growth profile.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound in Q2 2026 rests on normalization of Fragrance Ingredients, resilient Fine Fragrance execution amid Middle East volatility, and a rebuild of R&D and go-to-market for Consumer Fragrance. Management signals a mid‑single‑digit H2 for Fine Fragrance and low single-digit growth for Consumer Fragrance, underpinned by an improved R&D pipeline and a long-term push into 2027 with higher-value ingredients and delivery systems.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 results underscore a resilient Scent recovery driven by double-digit Fragrance Ingredients growth and solid Consumer Fragrance momentum, with a rebuilt R&D pipeline set to support growth into 2027. In the second half, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace as R&D and go-to-market improvements support market share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, a cautious but improving Fine Fragrance trajectory through Middle East volatility, and a Consumer Fragrance rebound driven by rebuilt R&D and go-to-market capabilities aimed at market-share gains. The plan emphasizes a multi-year R&D rebuild, a deep pipeline of molecules and delivery systems, and an innovation-first path to 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent's rebound to Fragrance Ingredients momentum, with Fine Fragrance stabilizing amid volatility and Consumer Fragrance propelled by an R&D-led recovery and go-to-market rebuild. The company expects a mid-single-digit 2H for Fine Fragrance and a low single-digit pace for Consumer Fragrance, supported by a strengthened R&D pipeline targeting 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-faceted Scent recovery driven by stabilizing Fine Fragrance demand, normalization of Consumer Fragrance through revamped R&D and go-to-market execution, and a shift toward higher-value Fragrance Ingredients. The firm also details a robust 2027 R&D plan designed to sustain competitive advantage with an strengthened pipeline, leading-edge perfumers, and sustained reinvestment in innovation, aligned to long-term growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi